remestemcel-L-rknd (Ryoncil)
Jump to navigation
Jump to search
Introduction
indications:
- treatment of glucorticoid-refractory graft vs host disease in pedicatric patients >= 2 years
Dosage
- 3.8 ml 6,680,000 mL injection
Mechanism of action
- allogeneic bone marrow-derived mesenchymal stromal cell therapy
More general terms
References
- ↑ FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. FDA: Dec 18, 2024 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric